<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Ferring and IMAB Sign Licensing Agreement Granting IMAB Exclusive Rights in Asia to Olamkicept for the Treatment of Autoimmune Disease	</title>
	<atom:link href="https://www.novumpr.nl/2016/12/19/ferring-and-imab-sign-licensing-agreement-granting-imab-exclusive-rights-in-asia-to-olamkicept-for-the-treatment-of-autoimmune-disease/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2016/12/19/ferring-and-imab-sign-licensing-agreement-granting-imab-exclusive-rights-in-asia-to-olamkicept-for-the-treatment-of-autoimmune-disease/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ferring-and-imab-sign-licensing-agreement-granting-imab-exclusive-rights-in-asia-to-olamkicept-for-the-treatment-of-autoimmune-disease</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Mon, 19 Dec 2016 10:11:16 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.2</generator>
</channel>
</rss>
